Results 11 to 20 of about 5,627 (198)

Immunotoxins: The Role of the Toxin [PDF]

open access: yesToxins, 2013
Immunotoxins are antibody-toxin bifunctional molecules that rely on intracellular toxin action to kill target cells. Target specificity is determined via the binding attributes of the chosen antibody. Mostly, but not exclusively, immunotoxins are purpose-
David FitzGerald, Antonella Antignani
doaj   +4 more sources

Mechanisms of Resistance to Immunotoxins Containing Pseudomonas Exotoxin A in Cancer Therapy

open access: yesBiomolecules, 2020
Immunotoxins are a class of targeted cancer therapeutics in which a toxin such as Pseudomonas exotoxin A (PE) is linked to an antibody or cytokine to direct the toxin to a target on cancer cells.
Michael Dieffenbach, Ira Pastan
doaj   +2 more sources

Development of Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer: An Update

open access: yesBiomolecules, 2020
Hepatocellular carcinoma (HCC) accounts for most liver cancers and represents one of the deadliest cancers in the world. Despite the global demand for liver cancer treatments, there remain few options available. The U.S. Food and Drug Administration (FDA)
Bryan D. Fleming, Mitchell Ho
doaj   +2 more sources

Plant Toxin-Based Immunotoxins for Cancer Therapy: A Short Overview [PDF]

open access: yesBiomedicines, 2016
Immunotoxins are chimeric proteins obtained by linking a toxin to either an intact antibody or an antibody fragment. Conjugation can be obtained by chemical or genetic engineering, where the latter yields recombinant conjugates.
Letizia Polito   +2 more
doaj   +2 more sources

Pseudomonas Exotoxin Immunotoxins and Anti-Tumor Immunity: From Observations at the Patient’s Bedside to Evaluation in Preclinical Models

open access: yesToxins, 2019
Immunotoxins are protein drugs composed of a targeting domain genetically fused to a protein toxin. One killing domain being explored is a truncated Pseudomonas exotoxin A (PE).
Yasmin Leshem, Ira Pastan
doaj   +2 more sources

Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A

open access: yesToxins, 2016
Recombinant immunotoxins (RITs) are fusions of an Fv-based targeting moiety and a toxin. Pseudomonas exotoxin A (PE) has been used to make several immunotoxins that have been evaluated in clinical trials.
Gilad Kaplan   +6 more
doaj   +2 more sources

Antibody-Based Immunotoxins for the Treatment of Cancer

open access: yesAntibodies, 2012
Antibody-based immunotoxins comprise an important group in targeted cancer therapeutics. These chimeric proteins are a form of biological guided missiles that combine a targeting moiety with a potent effector molecule.
Nurit Becker, Itai Benhar
doaj   +2 more sources

Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential

open access: yesInternational Journal of Nanomedicine, 2017
Yuan Yu,1–3 Jialu Li,1–3 Xuejun Zhu,4 Xiaowen Tang,2,5 Yangyi Bao,6 Xiang Sun,6 Yuhui Huang,1,2 Fang Tian,4 Xiaomei Liu,1,2 Lin Yang1–3 1The Cyrus Tang Hematology Center, 2Collaborative Innovation Center of Hematology, Soochow ...
Yu Y   +9 more
doaj   +1 more source

Ricin and Ricin-Containing Immunotoxins: Insights into Intracellular Transport and Mechanism of action in Vitro

open access: yesAntibodies, 2013
Ricin is a type II ribosome inactivating protein (RIP) isolated from castor beans. Its high toxicity classifies it as a possible biological weapon. On the other hand, ricin linked to specific monoclonal antibodies or used in other conjugates has powerful
Monika Słomińska-Wojewódzka   +1 more
doaj   +2 more sources

Immunotoxins Targeting B cell Malignancy—Progress and Problems With Immunogenicity

open access: yesBiomedicines, 2018
Few immunotoxins or targeted toxins have become mainline cancer therapies. Still immunotoxins continue to be of major interest and subject of research and development as alternative therapies for drug resistant cancer. A major matter of concern continues
Daniel A. Vallera, Robert J. Kreitman
doaj   +2 more sources

Home - About - Disclaimer - Privacy